Gt Biopharma Stock Probability of Future Stock Price Finishing Over 5.85
| GTBP Stock | USD 2.74 0.06 2.14% |
GTBP |
GT Biopharma Target Price Odds to finish over 5.85
The tendency of GTBP Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move over $ 5.85 or more in 90 days |
| 2.74 | 90 days | 5.85 | near 1 |
Based on a normal probability distribution, the odds of GT Biopharma to move over $ 5.85 or more in 90 days from now is near 1 (This GT Biopharma probability density function shows the probability of GTBP Stock to fall within a particular range of prices over 90 days) . Probability of GT Biopharma price to stay between its current price of $ 2.74 and $ 5.85 at the end of the 90-day period is about 37.22 .
Given the investment horizon of 90 days GT Biopharma has a beta of -0.0665. This usually indicates as returns on the benchmark increase, returns on holding GT Biopharma are expected to decrease at a much lower rate. During a bear market, however, GT Biopharma is likely to outperform the market. Additionally GT Biopharma has an alpha of 0.5089, implying that it can generate a 0.51 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). GT Biopharma Price Density |
| Price |
Predictive Modules for GT Biopharma
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as GT Biopharma. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.GT Biopharma Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. GT Biopharma is not an exception. The market had few large corrections towards the GT Biopharma's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold GT Biopharma, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of GT Biopharma within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.51 | |
β | Beta against Dow Jones | -0.07 | |
σ | Overall volatility | 0.46 | |
Ir | Information ratio | 0.08 |
GT Biopharma Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of GT Biopharma for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for GT Biopharma can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| GT Biopharma is way too risky over 90 days horizon | |
| GT Biopharma appears to be risky and price may revert if volatility continues | |
| GT Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: GT Biopharma Stock Rating Upgraded by Roth Capital |
GT Biopharma Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of GTBP Stock often depends not only on the future outlook of the current and potential GT Biopharma's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. GT Biopharma's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 1.3 M | |
| Cash And Short Term Investments | 14 M |
GT Biopharma Technical Analysis
GT Biopharma's future price can be derived by breaking down and analyzing its technical indicators over time. GTBP Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of GT Biopharma. In general, you should focus on analyzing GTBP Stock price patterns and their correlations with different microeconomic environments and drivers.
GT Biopharma Predictive Forecast Models
GT Biopharma's time-series forecasting models is one of many GT Biopharma's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary GT Biopharma's historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about GT Biopharma
Checking the ongoing alerts about GT Biopharma for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for GT Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| GT Biopharma is way too risky over 90 days horizon | |
| GT Biopharma appears to be risky and price may revert if volatility continues | |
| GT Biopharma has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (7.6 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| GT Biopharma currently holds about 23.73 M in cash with (8.85 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.76. | |
| Roughly 68.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: GT Biopharma Stock Rating Upgraded by Roth Capital |
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.